Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-130A-01 patch for maintenance of ovulation inhibition
NCT07365904Phase 2Recruiting
- Sponsor
- Mylan
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MR-130A-01 in contraception, sponsored by Mylan. Primary endpoint: Ovulation incidence in cycle with regular application and extended period application errors at 84 days. Started Dec 2025; status: recruiting.
02
Drugs
MR-130A-01
03
Conditions
contraception
Beyond the preview
Go deeper on NCT07365904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365904.